BTK and diffuse large B-cell lymphoma: Bruton’s tyrosine kinase (BTK) inhibitors, either alone or in combination, have been identified as a promising therapeutic option for systemic DLBCL (11, 12), particularly for cases with extranodal lesions and MCD genetic subtype.